Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AbbVie Anticipates $2.7B R&D Hit, Adjusts Full-Year Profit Outlook

In a significant development for the pharmaceutical industry, AbbVie has announced an expected $2.7 billion impact on its third-quarter financials, prompting a revision of its full-year earnings forecast. This substantial hit is attributed to acquired in-process research and development (IPR&D) expenses and milestone payments, reflecting the company's ongoing investment in future therapies and collaborations.

NoahAI News10/6/2025

FDA Approves IceCure Medical's ProSense for Breast Cancer Treatment

IceCure Medical, an Israeli medical technology company, has received FDA approval for its tumor-freezing treatment ProSense, marking a significant milestone in breast cancer therapy. The approval makes ProSense the first medical device of its kind to be endorsed for the local treatment of breast cancer, offering a minimally invasive alternative to traditional surgical interventions.

NoahAI News10/6/2025

Ignota Labs Acquires Kronos Bio's Pipeline, Breathing New Life into Shelved Drug Candidates

In a strategic move that highlights the growing trend of rescuing abandoned drug programs, UK-based Ignota Labs has acquired the clinical pipeline of Kronos Bio. This acquisition, valued at less than $300,000, marks a significant development in the pharmaceutical industry's approach to drug development and asset management.

NoahAI News10/6/2025

Talkspace Expands Mental Health Services with Wisdo Health Acquisition

Talkspace, a leading online therapy provider, has acquired Wisdo Health, an AI-powered coaching and peer-to-peer support platform, in a strategic move to broaden its mental health service offerings. This acquisition marks a significant development in the digital mental health landscape, addressing the growing need for comprehensive and accessible mental health support.

NoahAI News10/6/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Financial Pressures

The pharmaceutical and biotech sectors continue to grapple with significant workforce reductions as companies reevaluate priorities and seek to extend cash runways in a challenging economic environment. Recent months have seen a wave of layoffs affecting thousands of employees across the industry.

NoahAI News10/4/2025

Leadership Shakeup at NIH Amid Whistleblower Complaints and Policy Shifts

In a stunning turn of events, several high-ranking officials at the National Institutes of Health (NIH) have been terminated following whistleblower complaints, signaling a dramatic shift in the agency's leadership and potentially its scientific priorities.

NoahAI News10/4/2025

Amgen's Repatha Shows Promise in Cardiovascular Disease Prevention

Amgen's cholesterol-lowering drug Repatha (evolocumab) has demonstrated significant potential in preventing cardiovascular events in high-risk patients without prior heart disease, according to recent clinical trial results. This development could expand the drug's reach and solidify its position in the primary prevention market.

NoahAI News10/4/2025

Precision Neuroscience Unveils Groundbreaking Brain-Computer Interface Study

Precision Neuroscience, a leading developer of brain-computer interfaces (BCIs), has released a landmark study detailing the successful implementation of its minimally invasive Layer 7 cortical interface in human patients. The research, published in Nature Biomedical Engineering, marks a significant advancement in BCI technology, potentially revolutionizing treatment options for patients with paralysis, ALS, and other neurological conditions.

NoahAI News10/4/2025

FDA Approves Groundbreaking Combination Therapy for Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved a novel combination therapy for extensive-stage small cell lung cancer (ES-SCLC), setting a new benchmark for first-line treatment in this challenging disease. The approval, announced on October 3, 2025, greenlights the use of Jazz Pharmaceuticals' Zepzelca (lurbinectedin) in combination with Roche's Tecentriq (atezolizumab) as a first-line maintenance treatment for ES-SCLC patients who have not progressed after initial induction therapy.

NoahAI News10/4/2025

GoodRx Explores Partnership with TrumpRx, Expands Kroger Collaboration Amid Prescription Drug Pricing Developments

GoodRx, the prescription drug savings platform, has seen a significant boost in its stock value following announcements of potential collaborations and expanded partnerships in the pharmaceutical industry. The company's shares climbed by more than 14% this week, with a nearly 5% increase on Friday morning alone, as investors responded to news of a possible partnership with the newly announced government-run website, TrumpRx, and an expanded tie-up with national retail pharmacy chain Kroger.

NoahAI News10/4/2025

Cidara Secures $339M BARDA Funding for Non-Vaccine Flu Preventative as U.S. Shifts Away from mRNA

Cidara Therapeutics has landed a substantial federal contract to develop and manufacture its innovative non-vaccine flu preventative, CD388, in the United States. The deal comes as the U.S. government reevaluates its approach to influenza protection, moving away from mRNA-based technologies.

NoahAI News10/4/2025

Rocket Pharmaceuticals Halts FDA Approval Bid for Fanconi Anemia Gene Therapy

Rocket Pharmaceuticals has announced the withdrawal of its biologics license application (BLA) for RP-L102, a gene therapy aimed at treating Fanconi anemia, a rare genetic disorder characterized by bone marrow failure. This decision marks a significant shift in the company's strategic focus and pipeline priorities.

NoahAI News10/4/2025

«1...36 37 38...67 »